Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENeu: Recovery of IFN-beta Efficacy in RRMS
NCT00493116Phase 4Completed
- Sponsor
- Biogen
- Start
- Oct 2003
- Primary completion
- Dec 2009
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA. Started Oct 2003; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00493116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493116.